MVA based SARS-CoV-2 vaccines

NIH Pandemic-Era Grants

Pandemic Era Grants

2020

↗ Live URL (may be dead)

Document text

Principal Investigator: Rama Rao  Amara
Organization: EMORY UNIVERSITY
Fiscal Year: 2020
Award: $292,855
Funding agency: National Institute of Allergy and Infectious Diseases

The overall goal of this proposal is to develop effective prophylactic vaccines against the novel SARS
Coronavirus-2 (SARS-CoV-2) infection that has recently emerged as a pandemic across the world. The SARS-CoV-2 has already infected more than 120,000 people and over 4000 people died due to COVID-19, a disease
caused by SARS-CoV-2. Thus, there is an urgent need for the development of a vaccine that can rapidly induce
anti-viral immunity and prevent infection. Previous data from other related coronavirus infections such as SARS-CoV and MERS-CoV demonstrate that a strong neutralizing antibody response against the spike protein can
effectively prevent infection. Thus, a primary goal of this proposal is to develop a modified vaccinia Ankara (MVA)
based vaccine that expresses SARS-CoV-2 spike protein to generate a rapid and strong neutralizing antibody
response both in systemic and mucosal compartments. There are several advantages to MVA based vaccines
that include their excellent safety and a single dose of MVA vaccination can provide protection against multiple
virus infections including SARS-CoV, MERS, Zika and Ebola virus. A novel aspect of this proposal is that we
will compare the immunogenicity and protective ability of different forms of the spike protein with a goal of
inducing neutralizing antibodies against both SARS-CoV-2 and SARS-CoV. This proposal has two specific aims.
The goal of Aim 1 is to generate MVA vaccines and characterizing the anti-spike antibody response in mice. We
will also compare parenteral (i.m.) vs mucosal (intranasal) vaccinations to determine the best route for inducing
mucosal antibody response. The goal of Aim 2 is to evaluate the protective efficacy of the MVA-based SARS-CoV-2 vaccines. There is an urgent and unmet need to develop and characterize small animal models for
evaluating vaccine efficacy against SARS-CoV-2. Mice have served as an excellent model system to not only
understand immunity to the related SARS virus but also for evaluating vaccines and antiviral therapeutics. In this
Aim, we will develop and characterize a mouse model of SARS-CoV-2 infection and use this model to test the
protective efficacy of our MVA-based vaccine candidates. The completion of these studies will not only provide
a mouse model for SARS-CoV-2 infection but also develop vaccine candidates against SARS-CoV-2.

Terms: <2019 novel coronavirus><2019-nCoV><AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Animal Model><Animal Models and Related Studies><Antibodies><Antibody Affinity><Antibody Response><Antibody titer measurement><Antigenic Determinants><Antigens><Antiviral Agents><Antiviral Drugs><Antivirals><Autologous><Binding><Binding Determinants><Binding Sites><Biologic Models><Biological Models><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><COVID-19><COVID19><Cell membrane><Combining Site><Coronaviridae Infections><Coronavirus Infections><Cytoplasmic Membrane><Data><Disease><Disorder><Dose><EBOV><Ebola virus><Epitopes><Goals><HIV><Human><Human Immunodeficiency Viruses><Immunity><Immunization><Immunize><Immunologic Sensitization><Immunologic Stimulation><Immunological Sensitization><Immunological Stimulation><Immunostimulation><Individual><Infection><Infection prevention><LAV-HTLV-III><Length><Lymphadenopathy-Associated Virus><MERS corona virus><MERS coronavirus><MERS virus><MERS-CoV><Measures><Mice><Mice Mammals><Middle East Respiratory Syndrome Corona Virus><Middle East Respiratory Syndrome Coronavirus><Middle East Respiratory Syndrome Virus><Middle East Respiratory Syndrome-CoV><Middle Eastern Respiratory Syndrome Corona virus><Middle Eastern Respiratory Syndrome Coronavirus><Middle Eastern Respiratory Syndrome Virus><Middle Eastern Respiratory Syndrome-CoV><Model System><Modeling><Modern Man><Modified Vaccinia Ankara><Modified Vaccinia Virus Ankara><Molecular Interaction><Mucosa><Mucosal Tissue><Mucous Membrane><Murine><Mus><Plasma Membrane><Prevent infection><Preventative vaccine><Preventive vaccine><Prophylactic vaccine><Proteins><Reactive Site><Recombinants><Route><SARS Virus><SARS corona virus><SARS coronavirus><SARS-Associated Coronavirus><SARS-CoV><SARS-CoV-2><SARS-CoV2><SARS-Related Coronavirus><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Safety><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe acute respiratory syndrome coronavirus 2><Surface><T cell response><T8 Cells><T8 Lymphocytes><Testing><Therapeutic><Transgenic Mice><Vaccination><Vaccines><Viral Diseases><Virion><Virus><Virus Diseases><Virus Particle><Virus-HIV><Virus-like particle><Wuhan coronavirus><ZIKV><Zika Virus><anti-viral agents><anti-viral drugs><anti-viral immunity><anti-virals><antibody titering><antigen antibody affinity><antiviral immunity><base><corona virus disease 2019><coronavirus disease 2019><cross reactivity><develop a vaccine><development of a vaccine><ebolavirus><immunogen><immunogenicity><model of animal><model organism><monomer><mouse model><murine model><neutralizing antibody><novel><pandemic><pandemic disease><plasmalemma><protective efficacy><receptor binding><receptor bound><response><severe acute respiratory syndrome-CoV><vaccination study><vaccination trial><vaccine candidate><vaccine development><vaccine efficacy><vaccine formulation><vaccine study><vaccine trial><vector><viral infection><virus infection><virus-induced disease><virus-like nanoparticles><viruslike particle><zikav>